company background image
KZA

Kazia Therapeutics ASX:KZA Stock Report

Last Price

AU$0.24

Market Cap

AU$37.4m

7D

-3.0%

1Y

-80.8%

Updated

17 Aug, 2022

Data

Company Financials +
KZA fundamental analysis
Snowflake Score
Valuation5/6
Future Growth3/6
Past Performance0/6
Financial Health5/6
Dividends0/6

KZA Stock Overview

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs.

Kazia Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Kazia Therapeutics
Historical stock prices
Current Share PriceAU$0.24
52 Week HighAU$1.65
52 Week LowAU$0.23
Beta2.7
1 Month Change-55.09%
3 Month Change-69.50%
1 Year Change-80.83%
3 Year Change-30.71%
5 Year Change-43.61%
Change since IPO-92.87%

Recent News & Updates

Shareholder Returns

KZAAU BiotechsAU Market
7D-3.0%1.1%1.8%
1Y-80.8%-0.9%-5.7%

Return vs Industry: KZA underperformed the Australian Biotechs industry which returned -0.9% over the past year.

Return vs Market: KZA underperformed the Australian Market which returned -5.7% over the past year.

Price Volatility

Is KZA's price volatile compared to industry and market?
KZA volatility
KZA Average Weekly Movement17.2%
Biotechs Industry Average Movement11.5%
Market Average Movement10.6%
10% most volatile stocks in AU Market17.7%
10% least volatile stocks in AU Market4.6%

Stable Share Price: KZA is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 17% a week.

Volatility Over Time: KZA's weekly volatility has increased from 12% to 17% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1994n/aJames Garnerhttps://www.kaziatherapeutics.com

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer.

Kazia Therapeutics Fundamentals Summary

How do Kazia Therapeutics's earnings and revenue compare to its market cap?
KZA fundamental statistics
Market CapAU$37.41m
Earnings (TTM)-AU$15.08m
Revenue (TTM)AU$15.19m

2.4x

P/S Ratio

-2.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
KZA income statement (TTM)
RevenueAU$15.19m
Cost of RevenueAU$0
Gross ProfitAU$15.19m
Other ExpensesAU$30.27m
Earnings-AU$15.08m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.10
Gross Margin100.00%
Net Profit Margin-99.27%
Debt/Equity Ratio0.0%

How did KZA perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is KZA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for KZA?

Other financial metrics that can be useful for relative valuation.

KZA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.5x
Enterprise Value/EBITDA-1.9x
PEG Ration/a

Price to Sales Ratio vs Peers

How does KZA's PS Ratio compare to its peers?

KZA PS Ratio vs Peers
The above table shows the PS ratio for KZA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average19.5x
ATX Amplia Therapeutics
9.7xn/aAU$19.0m
NSB NeuroScientific Biopharmaceuticals
36.7xn/aAU$35.9m
DXB Dimerix
10.8xn/aAU$51.3m
PAB Patrys
19.3xn/aAU$55.5m
KZA Kazia Therapeutics
2.4x47.8%AU$37.4m

Price-To-Sales vs Peers: KZA is good value based on its Price-To-Sales Ratio (2.4x) compared to the peer average (19.5x).


Price to Earnings Ratio vs Industry

How does KZA's PE Ratio compare vs other companies in the AU Biotechs Industry?

Price-To-Sales vs Industry: KZA is good value based on its Price-To-Sales Ratio (2.4x) compared to the Australian Biotechs industry average (20x)


Price to Sales Ratio vs Fair Ratio

What is KZA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

KZA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.4x
Fair PS Ratio25.2x

Price-To-Sales vs Fair Ratio: KZA is good value based on its Price-To-Sales Ratio (2.4x) compared to the estimated Fair Price-To-Sales Ratio (25.2x).


Share Price vs Fair Value

What is the Fair Price of KZA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: KZA (A$0.24) is trading below our estimate of fair value (A$15.82)

Significantly Below Fair Value: KZA is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Kazia Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

3/6

Future Growth Score 3/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


51.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: KZA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: KZA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: KZA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: KZA's revenue (47.8% per year) is forecast to grow faster than the Australian market (5.7% per year).

High Growth Revenue: KZA's revenue (47.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: KZA's Return on Equity is forecast to be very high in 3 years time (63.6%).


Discover growth companies

Past Performance

How has Kazia Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-6.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: KZA is currently unprofitable.

Growing Profit Margin: KZA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: KZA is unprofitable, and losses have increased over the past 5 years at a rate of 6.3% per year.

Accelerating Growth: Unable to compare KZA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: KZA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.5%).


Return on Equity

High ROE: KZA has a negative Return on Equity (-59.16%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Kazia Therapeutics's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: KZA's short term assets (A$16.7M) exceed its short term liabilities (A$7.6M).

Long Term Liabilities: KZA's short term assets (A$16.7M) exceed its long term liabilities (A$11.6M).


Debt to Equity History and Analysis

Debt Level: KZA is debt free.

Reducing Debt: KZA has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: KZA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: KZA has less than a year of cash runway if free cash flow continues to grow at historical rates of 4.1% each year.


Discover healthy companies

Dividend

What is Kazia Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate KZA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate KZA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if KZA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if KZA's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as KZA has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

5.4yrs

Average management tenure


CEO

James Garner (49 yo)

6.5yrs

Tenure

AU$1,132,636

Compensation

Dr. James Garner, MA, MBA, MBBS, BSC (Hons), MAICD, has been the Chief Executive Officer, Managing Director and Executive Director of Kazia Therapeutics Limited (formerly Novogen Limited) since February 1,...


CEO Compensation Analysis

Compensation vs Market: James's total compensation ($USD794.33K) is above average for companies of similar size in the Australian market ($USD282.47K).

Compensation vs Earnings: James's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: KZA's management team is seasoned and experienced (5.4 years average tenure).


Board Members

Experienced Board: KZA's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.4%.


Top Shareholders

Company Information

Kazia Therapeutics Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Kazia Therapeutics Limited
  • Ticker: KZA
  • Exchange: ASX
  • Founded: 1994
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: AU$37.409m
  • Shares outstanding: 149.64m
  • Website: https://www.kaziatherapeutics.com

Location

  • Kazia Therapeutics Limited
  • Three International Towers
  • Level 24
  • Sydney
  • New South Wales
  • 2000
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/17 00:00
End of Day Share Price2022/08/17 00:00
Earnings2021/12/31
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.